# Sheng Wei Kun Teng

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sheng-wei-kun-teng

- Industry: Medical Devices & Equipment
- Headquarters: Changsha, China
- Total disclosed funding: $27M
- Latest round: Series A (Dec 22, 2024)
- Investors on record: 3

## About

Based in Changsha, China, Sheng Wei Kun Teng operates as a medical device manufacturer, mainly engaged in the research and development and sales of medical devices and experimental analysis instruments. The company has set up a subsidiary, QuantuMDx Group Ltd., in UK. Its product has acuqired EU CE certification. In December 2024, Sheng Wei Kun Teng raised approximately CNY 200 million in series A funding from new investors Sansure Biotech Inc., Voyagers Capital, and Rongquan Venture Capital.

Sheng Wei Kun Teng focuses on providing next generation molecular POCT (point-of-care testing) platform. Its main product, the Q-POC™ instrument, is a molecular diagnostic device that can be used for a variety of molecular diagnostic tests, including joint detection of pathogens for complex infectious diseases, screening for drug-resistant genes, genetic testing for personalized medication, and early cancer screening.

The company generates revenue by molecular diagnostic equipment.

The company will use the series A funding for the research and development and industrialization base construction of the new generation of molecular POCT products.

## Funding rounds

- Series A, Dec 22, 2024, $27M — Sansure Biotech Inc., Shengwei Rongquan Capital, Voyagers Capital

## Investors

- Sansure Biotech Inc. — Series A
- Shengwei Rongquan Capital — Series A
- Voyagers Capital (https://capitalatlas.ai/funds/voyagers-capital) — Series A